Improved Survival in Subset of Advanced Pancreatic Cancer
Adding nimotuzumab to gemcitabine significantly improved survival outcomes in a subset of patients with KRAS wild-type advanced pancreatic cancer.
Source: medscape.com
Stay updated with breaking news from Biliary Obstruction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding nimotuzumab to gemcitabine significantly improved survival outcomes in a subset of patients with KRAS wild-type advanced pancreatic cancer.
Physicians and patients should be aware of potential for gallbladder or biliary diseases with GLP-1 agonists, especially in high doses used for weight loss, meta-analysis authors conclude.